Clinical Trial Update: A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease. [Phase 2]

View source ↗

Summary

Phase 2 trial assessing pharmacodynamics, safety, and tolerability of PF-05221304 and PF-06865571 co-administered for 6 weeks in adults with non-alcoholic fatty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• PF-05221304
• PF-06865571

Snippet

Sponsor: Pfizer | Conditions: Non-Alcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Status: COMPLETED | Results posted: 2020-09-23